Partner Headlines - TEVA

  1. Israeli Tech Startups Attract Record Funding In Q2

    IBD
  2. 5 Top Medical Stocks Reporting Earnings This Week

    IBD
  3. Teva's Deal-Making Spurs Inflows To Israel ETFs

    Benzinga
  4. Benzinga's Top Upgrades

    Benzinga
  5. IBD 50: 10 Top Stocks Reporting Earnings This Week

    IBD
  6. These 4 Foreign Drug Stocks Have Broken Out Recently

    IBD
  7. 5 Hot Drug Stocks Top IBD's Big Cap Leaders Screen

    IBD
  8. Wakefulness Drug Xyrem Keeps Jazz Pharmaceuticals Up

    IBD
  9. Amgen Stock Clears Buy Point Ahead Of Earnings

    IBD
  10. Stocks In Rebound Mode; Icon, Cadence Break Out

    IBD
  11. Can Health Care Sector Continue its Incredible Run?

    FoxBusiness
  12. Weekly 52-Week Highs Highlight: GIS, AAP, BCR, TEVA

    GuruFocus
  13. Benzinga's Top Upgrades

    Benzinga
  14. Teva Announces European Medicines Agency (EMA) Confirms Successful ...

    Benzinga
  15. Teva Prefers Allergan Unit

    IBD
  16. Benzinga's M&A Chatter for Monday July 27, 2015

    Benzinga
  17. Stocks Fall For Fifth Straight Session On China Woes

    IBD
  18. Allergan CEO: Teva Made A 'Compelling Offer' We Couldn't Refuse

    Benzinga
  19. Market Update: Monday's Top 10 Volume Movers

    Benzinga
  20. Stocks Mired In Red, Hurt By China Weakness; Boot Barn Bounces

    IBD
  21. Market Update: Monday's Mid-Day Movers, China's Stock Market ...

    Benzinga
  22. Stocks In The Red But Off Lows As Shanghai, Europe Weigh

    IBD
  23. Teva Drops Mylan Chase To Buy Allergan Generics Unit

    IBD
  24. Benzinga's Volume Movers

    Benzinga
  25. Teva Confirms Allergan Generics Buy, Drops Mylan Bid

    IBD
  26. U.S. Stocks On Track For Weak Open As Chinese Stocks Sink

    IBD
  27. UPDATE: Mylan Issues Comment on Teva Deal to Buy Allergan's Generic ...

    Benzinga
  28. UPDATE: Teva Withdraws Proposal to Acquire Mylan

    Benzinga
  29. UPDATE: Teva to Acquire Allergan Generics for $40.5 B

    Benzinga
  30. Benzinga's Weekend M&A Chatter

    Benzinga
  31. Teva To Buy Allergan's Generic Drug Unit, Unit Worth ~$45B, Deal ...

    Benzinga
  32. Biotech IPO Boom Gaining Thrust With NantKwest Debut

    IBD
  33. Morning-after pill use increases

    IBD
  34. Novartis' Mixed Q2: Sandoz Booms, Alcon Struggles

    IBD
  35. Rapid7 IPO Pops 52%; Investors Hungry For Blue Buffalo

    IBD
  36. Painkiller Abuse Drives Drugmakers To Innovate

    IBD
  37. Celgene Hits High As Street Applauds Receptos Buyout

    IBD
  38. Teva-Mylan merger opposed

    IBD
  39. Benzinga's Top Initiations

    Benzinga
  40. Medicines Co., Eagle Pharma Up On Analyst Actions

    IBD
  41. Momenta Pharma

    IBD
  42. Momenta Downgraded After Stock Price Doubles

    IBD
  43. Teva-Xenon Arthritis Pain Drug Fails Midstage Trial

    IBD
  44. Wednesday's Mid-Day Movers: Chubb, Rock Creed, RADA Win; Peabody ...

    Benzinga
  45. Unusual Covered Call Opportunity Teva Pharmaceuticals

    Benzinga
  46. Alder Bio Up As Credit Suisse Lauds Migraine Drug

    IBD
  47. New America's IPO Stock Winners: Fitbit, Arista

    IBD
  48. ObamaCare Enables Health Insurer Merger Mania

    IBD
  49. Paul Tudor Jones Buys Stakes in ADP and Visa

    GuruFocus
  50. Teva Migraine Drug Succeeds In Midstage Trial

    IBD
  51. Teva Migraine Drug Succeeds In Midstage Trial

    IBD
  52. Teva to Present New Findings at the American Headache Society ...

    Benzinga
  53. How High Can Eagle Pharmaceuticals Fly On Teva Deal?

    IBD
  54. Teva's Mylan bid hits snag

    IBD
  55. Teva's Auspex Buyout Pays, But Mylan Bid Hits Snag

    IBD
  56. Teva Advances Pipeline of Movement Disorder Assets with Announcement ...

    Benzinga
  57. Top Biotech Stock Files For New Drug, In Buy Range

    IBD
  58. Activist Hedge Fund Manager Has Strong Focus on Health Care Stocks

    GuruFocus
  59. New Migraine Drugs Could Ease Investors' Headaches

    IBD
  60. Benzinga's M&A Chatter for Tuesday June 9, 2015

    Benzinga
  61. Leon Cooperman's Top Holdings Look Attractive

    GuruFocus
  62. Teva Pharmaceuticals

    IBD
  63. 6-K from Teva Pharma Shows Letter from CEO Vigodman, Chair Peterburg ...

    Benzinga
  64. Mobileye Hangs Just Below Buy Point In Deep Cup Base

    IBD
  65. Perrigo buys Glaxo OTC drugs

    IBD
  66. Will Perrigo's Glaxo Buy Make It Too Pricey?

    IBD
  67. Mylan Sends Letter to Teva CEO

    Benzinga
  68. Teva Announces Exclusive Launch of Generic Actonel Tablets in ...

    Benzinga
  69. Teva to pay $1.2 bil to settle

    IBD
  70. Regeneron, Lannett Among The 4 Top-Rated Drug Stocks

    IBD
  71. Benzinga's M&A Chatter for Wednesday May 27, 2015

    Benzinga
  72. TEVA PHARMA

    IBD
  73. Actavis Stock - A Must Have For Long-Term Investors

    GuruFocus
  74. Big Pharma Companies Are Betting On Regenerative Medicine - Should ...

    GuruFocus
  75. Stanley Druckenmiller's Top 5 New Stocks

    GuruFocus
  76. Endo International Acquires Par Pharmaceuticals For $8 Billion

    GuruFocus
  77. Endo Buying Par Pharma To Become Top Generics Player

    IBD
  78. IPO Stock Watch: Alder Soars On Migraine Drug Results

    IBD
  79. U.S. Loves Europe As Pharma, Energy Boost M&A

    IBD
  80. Actavis Offers Post-Allergan Guidance; Ligand Jumps

    IBD
  81. Actavis Q1 Beats Estimates, Includes Allergan In 2015 Guidance

    IBD
  82. Benzinga's Weekend M&A Chatter

    Benzinga
  83. Report: Mylan Might See Higher Bid From Teva

    Benzinga
  84. Jim Chanos, Kyle Bass Rip Oil And Pharma At SALT 2015

    Benzinga
  85. Alexion's $8.4 Billion Synageva Buyout Spooks Street

    IBD
  86. Leading Stock Mallinckrodt Delivers Strong Results As Base Forms

    IBD
  87. Mylan Q1 Mixed; Abiomed, Mallinckrodt, Zoetis Beat

    IBD
  88. Report Sees 'Cognitive Dissonance' In Mylan's Internal Price ...

    Benzinga
  89. M&A Fever Grips Drugmakers

    IBD
  90. Is The Drug Industry's Wedding Dance Nearly Finished?

    IBD
  91. Gilead's Strong Profit Tops Mixed Drug maker Reports

    IBD
  92. Teva tops as it tries for Mylan

    IBD
  93. Teva, Celgene, Novo Nordisk, Shire Report Q1 Earnings

    IBD
  94. Teva Beats Q1 Estimates, Raises Full-Year Forecast

    Benzinga
  95. Mylan Raises Perrigo Bid, But Perrigo Still Says No

    IBD
  96. Benzinga's M&A Chatter for Monday April 27, 2015

    Benzinga
  97. Mylan Rejects 'Low Quality'

    IBD
  98. Nasdaq Leads Market Lower As Medical Stocks Tumble

    IBD
  99. 4 Drug Giants Reporting Earnings This Week

    IBD
  100. Mylan Rejects Teva Bid After Raising Bid For Perrigo

    IBD
Trading Center
×

You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!